SCHEMBL10070083

SCHEMBL10070083

Cc1ccc(OC(=O)N2CCC(c3nc(-c4cc(F)cc(F)c4)n[nH]3)CC2)c(C)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RY12 Q9H244 1/20 0.40
TLR9 Q9NR96 4/20 0.39
TLR8 Q9NR97 4/20 0.39
TLR7 Q9NYK1 4/20 0.39
KIT P10721 3/20 0.38
HSD11B1 P28845 1/20 0.38
CPT1A P50416 2/20 0.37
GPR119 Q8TDV5 1/20 0.36
FASN P49327 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
AKT1 P31749 1/20 0.35
AKT2 P31751 1/20 0.35
HTT P42858 2/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
HPGD P15428 1/20 0.35
TRPC3 Q13507 1/20 0.35
HSD17B10 Q99714 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10069718 0.92 CPT1A (0.45) P2RY12TLR9TLR8TLR7KIT
SCHEMBL10070549 0.92 KIT (0.44) P2RY12TLR9TLR8TLR7KIT
SCHEMBL10070550 0.87 CPT1A (0.40) P2RY12TLR9TLR8TLR7KIT
SCHEMBL10070093 0.84 CPT1A (0.40) P2RY12TLR9TLR8TLR7KIT
SCHEMBL10070075 0.84 CPT2 (0.45) P2RY12HSD11B1CPT1AFASNAKT1
SCHEMBL10070536 0.80 CPT1A (0.46) P2RY12TLR9TLR8TLR7KIT
SCHEMBL10070076 0.80 KIT (0.44) P2RY12TLR9TLR8TLR7KIT
SCHEMBL10070063 0.79 HTT (0.48) CPT1AGPR119MEN1KMT2AHTT
SCHEMBL10040568 0.78 USP7 (0.41) HSD11B1MEN1KMT2AHTTKDM4E
SCHEMBL10069712 0.77 CPT1A (0.48) P2RY12TLR9TLR8TLR7KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8207199-B2 Azole compound ASTELLAS PHARMA INC. (JP) 2012-06-26 US disclosed
US-20110118311-A1 AZOLE COMPOUND ASTELLAS PHARMA INC. (JP) 2011-05-19 US disclosed
WO-2010007966-A1 AZOLE COMPOUND アステラス製薬株式会社 (JP) 2010-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118311-A1 AZOLE COMPOUND FAAH, FAAH2, TRPV1 P2RY12 139/4885TLR9 2889/4885TLR8 1454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.